The GLP is committed to full transparency. Download and review our 2019 Annual Report

Missing disease: Less-expensive whole-exome sequencing may flub diagnoses

| | May 9, 2017

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

A common DNA test used to find genes linked with disease may miss key genetic risk indicators, new research suggests.

Whole-exome sequencing—a technology that saves time and money by sequencing only protein-coding regions and not the entire genome—has been used in many studies to identify genes associated with disease, and by clinical labs to diagnose patients with genetic disorders.

However, the new research shows that these studies may routinely miss mutations in a subset of disease-causing genes that occur in regions of the genome that the cost-saving technology reads less often. A paper describing the research appears in the journal Scientific Reports.

“Although it was known that coverage—the average number of times a given piece of DNA is read during sequencing—could be uneven in whole-exome sequencing, our new methods are the first to really quantify this,” says coauthor Santhosh Girirajan, assistant professor of biochemistry and molecular biology and of anthropology at Penn State.

“Until the costs of whole-genome sequencing is no longer a barrier,” Girirajan says, “human genetics researchers should be aware of these limitations in whole-exome sequencing technologies.”

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: DNA test may miss some disease-causing genes

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend